Association between patient characteristics and biochemical monitoring within 2 weeks post-initiation of AA
| OR (95% CI) | ||
| Age and sex adjusted | Fully adjusted | |
| Male | Ref | Ref |
| Female | 0.90 (0.83 to 0.98) | 0.90 (0.82 to 0.98) |
| Age (years) | ||
| <50 | 0.54 (0.43 to 0.67) | 0.58 (0.46 to 0.73) |
| 50–59 | 0.72 (0.61 to 0.84) | 0.78 (0.66 to 0.91) |
| 60–64 | 0.81 (0.68 to 0.96) | 0.86 (0.72 to 1.03) |
| 65–69 | 0.94 (0.81 to 1.09) | 0.96 (0.83 to 1.12) |
| 70–75 | Ref | Ref |
| 76–79 | 0.90 (0.83 to 0.98) | 0.95 (0.82 to 1.10) |
| ≥80 | 1.05 (0.92 to 1.20) | 0.97 (0.85 to 1.11) |
| eGFR category (mL/min/1.73 m2) | ||
| ≥60 | Ref | Ref |
| 45–59 | 1.10 (0.99 to 1.23) | 1.13 (1.01 to 1.27) |
| 30–44 | 1.25 (1.10 to 1.42) | 1.29 (1.14 to 1.46) |
| 15–29 | 1.65 (1.33 to 2.06) | 1.74 (1.40 to 2.16) |
| Comorbidities | ||
| Hypertension | 1.03 (0.93 to 1.13) | 0.98 (0.88 to 1.09) |
| IHD | 1.00 (0.92 to 1.09) | 0.98 (0.89 to 1.07) |
| Heart failure | 1.05 (0.96 to 1.15) | 1.01 (0.92 to 1.11) |
| Arrhythmia | 1.09 (1.00 to 1.19) | 1.07 (0.98 to 1.18) |
| Diabetes | 1.06 (0.97 to 1.16) | 1.05 (0.95 to 1.15) |
| Peripheral arterial disease | 1.12 (0.98 to 1.27) | 1.08 (0.93 to 1.24) |
| Calendar time | ||
| 2004–2006 | Ref | Ref |
| 2007–2009 | 1.22 (1.07 to 1.38) | 1.21 (1.07 to 1.38) |
| 2010–2014 | 1.34 (1.17 to 1.53) | 1.35 (1.18 to 1.55) |
| Baseline potassium (mmol/L) | ||
| <5.0 | Ref | Ref |
| 5.0–5.5 | 1.05 (0.91 to 1.20) | 0.98 (0.86 to 1.12) |
| >5.5 | 0.98 (0.73 to 1.30) | 0.90 (0.68 to 1.20) |
Fully adjusted: adjusted for age, gender, eGFR category, hypertension, heart failure, ischaemic heart disease, arrhythmias, diabetes, peripheral arterial disease, baseline potassium and calendar time. Further adjustment for lifestyle covariates made marginal difference to all results, thus these variables are not included in models shown.
AA, aldosterone antagonist; eGFR, estimated glomerular filtration rate; IHD, ischaemic heart disease.